At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 76 enrolled
Drug / intervention
ILV-094drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
AN ASCENDING MULTIPLE DOSE STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND CLINICAL EFFICACY OF ILV-094 ADMINISTERED SUBCUTANEOUSLY OR INTRAVENOUSLY TO SUBJECTS WITH PSORIASIS
Wyeth is now a wholly owned subsidiary of Pfizer·interventional·Posted Nov 26, 2007·Updated Aug 23, 2024
In Brief
A Phase 1 clinical trial evaluating ILV-094 for Psoriasis. Completed, enrolled 76 participants across 24 sites in 4 countries.
Detailed Summary
The purpose of this study is to assess safety, and tolerability of multiple doses of ILV-094 administered to subjects with psoriasis
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesCanada, Hong Kong, South Africa, United States
Collaborators--
Timeline
Phase 1CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 2007
Enrollment StartDec 2007
Primary CompletionJun 2010
TodayJul 2026
First PostedNov 26, 2007
Enrollment StartDec 20, 2007
Primary CompletionJun 14, 2010
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 18.6 years ago
Interventions
ILV-094drug
SC and IV administration on days 1, 14, 28, and 42